Startups
Coultreon Biopharma
Clinical-stage biotechnology company developing oral small-molecule treatments for autoimmune and chronic inflammatory diseases. Formerly Onco3R Therapeutics, it uses salt-inducible kinase biology and an AI-augmented drug-design platform to optimize medicines. Its lead candidate COL-5671 is a selective, once-daily oral SIK3 inhibitor in Phase 1 development, with planned Phase 2 studies in psoriasis and ulcerative colitis. It also has discovery programs in immunology and metabolic disease.
Team
Fabrice KolbHead of Immunology; Co-founder |
François GonzalvezCo-founder |
Gert De BeckkerHead of Regulatory |
Guy PeetersChief Financial Officer; Co-founder |
John-Paul GallivanHead of Development; Co-founder |
Joost KolkmanCo-founder |
Lawrence BlattBoard member |
Lieve LammensToxicology |
Maha KatabiBoard member |
Marie De VulderChief Legal Officer; Co-founder |
 Max KlementBoard member |
Nate MassariChief Business Officer |
Pierre RaboissonChief Executive Officer; Chief Scientific Officer; Co-founder; Board Member |
Pieter PeetersOperating & Technology Officer; Co-founder |
Prista CharuwornChief Medical Officer |
Rogier RooswinkelBoard member |
Sandrine VendevilleCo-founder |
Tom GovaertsChemistry, Manufacturing and Controls |